Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125962862 | 12596286 | 2 | F | 20160720 | 20160817 | 20160727 | 20160819 | EXP | CO-ROCHE-1801420 | ROCHE | 60.19 | YR | F | Y | 0.00000 | 20160819 | OT | CO | CO |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125962862 | 12596286 | 1 | PS | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | 50722 | 1 | G | CAPSULE | Q12H | |||||||
| 125962862 | 12596286 | 2 | SS | Valixa | VALGANCICLOVIR | 1 | Oral | 21304 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125962862 | 12596286 | 1 | Renal transplant |
| 125962862 | 12596286 | 2 | Antiviral prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125962862 | 12596286 | DE |
| 125962862 | 12596286 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125962862 | 12596286 | Metabolic acidosis | |
| 125962862 | 12596286 | Pneumonia | |
| 125962862 | 12596286 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125962862 | 12596286 | 1 | 20160710 | 0 | ||
| 125962862 | 12596286 | 2 | 20160714 | 0 |